CDKN2A and neoplasm: In examining changes in p16—a tumor suppressor and known PD biomarker of DNMT inhibitors—we measured treatment-induced increases in the number of promoter hypomethylation sites for the p16-encoding gene CDKN2A in tumor specimens from 7 of the 8 assessed patients.